Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Jim McMannis who wrote (320317)	1/12/2007 11:33:14 AM
From: Road Walker	Respond to of 1574006

House likely to approve Medicare bill By KEVIN FREKING, Associated Press Writer 46 minutes ago A veto threat from President Bush didn't deter Democrats from pushing legislation Friday that would require the government to negotiate drug prices for Medicare patients. The House began debating the bill that would require the secretary of Health and Human Services to conduct those negotiations. It's one of Speaker Nancy Pelosi (news, bio, voting record)'s six priorities for the new Democratic-controlled House. Democrats touted the negotiations as a way to save money for seniors and taxpayers. They said that the government would be able to drive down prices by buying in bulk. "Medicare overpays drug companies in purchasing medicine," said the bill's author, Rep. John Dingell (news, bio, voting record), D-Mich. Republicans countered that the drug benefit, which kicked in on Jan. 1, 2006, has cost less than anticipated, and the large majority of seniors and disabled who use the program are satisfied. "With all that's right with the program, it seems unwise and unkind to jeopardize its success," said Rep. Michael Burgess (news, bio, voting record), R-Texas. Bush said Thursday that competition is already reducing prices for seniors and creating an environment that encourages the development of new drugs. "Government interference impedes competition, limits access to lifesaving drugs, reduces convenience for beneficiaries and ultimately increases costs to taxpayers, beneficiaries and all American citizens alike," the administration said in a written statement. Presidents have vetoed 1,485 bills during the nation's history. Congress overrode only 106 of them, according to the Congressional Research Service. Such overrides require that two-thirds of those present in each chamber vote to override the president's veto. Currently, private drug plans negotiate how much they'll pay for the medicine their customers take. Those plans get a federal subsidy, plus consumers pay for a portion of the medicine. Dingell said the government can do better than individual insurance companies in getting discounts. "The president and his Republicans allies have argued that this bill would do nothing. Then why, I must ask, would he bother to veto it?" said Dingell, chairman of the House Energy and Commerce Committee. Democrats have said that savings produced by the negotiations would be used to reduce a coverage gap that is common in many plans. Reducing the gap, known as the doughnut hole, would lower those beneficiaries' out-of-pocket costs. But Republicans counter that there wouldn't be any savings. Also, the nonpartisan Congressional Budget Office said the legislation was unlikely to result in savings to taxpayers. The program cost about $30 billion in its first year.Insurance companies offer competing coverage plans, and seniors may enroll in the one they like best. The administration announced on Wednesday that 23.5 million seniors had enrolled in stand-alone plans as of Jan. 1. While a majority of seniors are expressing satisfaction with the program, surveys also indicate that they overwhelmingly want the government to have the power to negotiate drug prices. A survey of seniors for the Kaiser Family Foundation showed that about 81 percent of seniors want to let the government use its buying power to negotiate drug prices, including 67 percent who said they strongly favor such negotiations. The issue is expected to have a tougher time in the Senate. However, Sen. Max Baucus (news, bio, voting record), D-Mont., gave supporters of the measure a lift on Thursday when he said the total prohibition on government negotiations for Medicare beneficiaries should be eliminated. "I do not buy the argument that the sky will fall on the prescription drug market if we remove this clause," said Baucus, chairman of the Senate Finance Committee, which has jurisdiction over Medicare.